Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07611214 · ClinicalTrials.gov registry record · Phase 4
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
A Phase 4 study, sponsored by Aurinia Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT07611214 is a Phase 4 study that is actively recruiting participants, run by Aurinia Pharmaceuticals. The registered enrollment target is 150 participants.
The verdict
NCT07611214, a Phase 4 study, is actively recruiting participants, sponsored by Aurinia Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
Interventions
- DRUG LUPKYNIS
- BIOLOGICAL belimumab, obinutuzumab or anifrolumab
- DRUG mycophenolic acid analog (MPAA)
- DRUG corticosteroid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-04-22 |
| Est. Completion | 2029-03-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07611214
The ClinicalTrials.gov registry entry for NCT07611214 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aurinia Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LUPKYNIS is the first listed.
NCT07611214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07611214 about?
NCT07611214 is a clinical study titled "PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis". The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
What is the current status of trial NCT07611214?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2026-04-22. Estimated completion is 2029-03-02.
What interventions are being tested in trial NCT07611214?
The interventions under investigation include: LUPKYNIS (DRUG), belimumab, obinutuzumab or anifrolumab (BIOLOGICAL), mycophenolic acid analog (MPAA) (DRUG), corticosteroid (DRUG).
Who is sponsoring clinical trial NCT07611214?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.